Valeant Pharmaceuticals International, Inc.·4/A

Apr 11, 7:00 PM ET

Loberg Philip Walden Jr 4/A

4/A · Valeant Pharmaceuticals International, Inc. · Filed Apr 11, 2011

Insider Transaction Report

Form 4/AAmended
Period: 2010-12-22
Loberg Philip Walden Jr
EVP, Interim CFO
Transactions
  • Award

    Common Stock, no par value

    2010-12-22+694130,065 total
Footnotes (2)
  • [F1]Represents dividend equivalents accrued on performanced bases restricted share units (PSUs) as a result of a dividend paid on the common stock of Valeant Pharmaceuticals International, Inc. on December 22, 2010.
  • [F2]This amendment is being filed to correct the number of PSUs that were reported in the original filing.

Documents

1 file
  • 4
    primary_doc.xml

    PRIMARY DOCUMENT